Aravind Krishnan1, Tim Xu1, Susan Hutfless2,3, Angela Park1, Thomas Stasko4, Allison T Vidimos5, Barry Leshin6, Brett M Coldiron7, Richard G Bennett8, Victor J Marks9, Rebecca Brandt9, Martin A Makary1,10, John G Albertini6,11. 1. Department of Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland. 2. Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 4. Department of Dermatology, University of Oklahoma, Oklahoma City. 5. Cleveland Clinic, Cleveland, Ohio. 6. The Skin Surgery Center, Winston-Salem, North Carolina. 7. University of Cincinnati Hospital, Cincinnati, Ohio. 8. Bennett Surgery Center, Santa Monica, California. 9. American College of Mohs Surgery, Milwaukee, Wisconsin. 10. Department of Health Policy, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 11. Department of Plastic and Reconstructive Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Abstract
Importance: Outlier physician practices in health care can represent a significant burden to patients and the health system. Objective: To study outlier physician practices in Mohs micrographic surgery (MMS) and the associated factors. Design, Setting, and Participants: This retrospective analysis of publicly available Medicare Part B claims data from January 2012 to December 2014 includes all physicians who received Medicare payments for MMS from any practice performing MMS on the head and neck, genitalia, hands, and feet region of Medicare Part B patients. Main Outcomes and Measures: Characteristics of outlier physicians, defined as those whose mean number of stages for MMS was 2 standard deviations greater than the mean number for all physicians billing MMS. Logistic regression was used to study the physician characteristics associated with outlier status. Results: Our analysis included 2305 individual billing physicians performing MMS. The mean number of stages per MMS case for all physicians practicing from January 2012 to December 2014 was 1.74, the median was 1.69, and the range was 1.09 to 4.11. Overall, 137 physicians who perform Mohs surgery were greater than 2 standard deviations above the mean (2 standard deviations above the mean = 2.41 stages per case) in at least 1 of the 3 examined years, and 49 physicians (35.8%) were persistent high outliers in all 3 years. Persistent high outlier status was associated with performing Mohs surgery in a solo practice (odds ratio, 2.35; 95% CI, 1.25-4.35). Volume of cases per year, practice experience, and geographic location were not associated with persistent high outlier status. Conclusions and Relevance: Marked variation exists in the number of stages per case for MMS for head and neck, genitalia, hands, and feet skin cancers, which may represent an additional financial burden and unnecessary surgery on individual patients. Providing feedback to physicians may reduce unwarranted variation on this metric of quality.
Importance: Outlier physician practices in health care can represent a significant burden to patients and the health system. Objective: To study outlier physician practices in Mohs micrographic surgery (MMS) and the associated factors. Design, Setting, and Participants: This retrospective analysis of publicly available Medicare Part B claims data from January 2012 to December 2014 includes all physicians who received Medicare payments for MMS from any practice performing MMS on the head and neck, genitalia, hands, and feet region of Medicare Part B patients. Main Outcomes and Measures: Characteristics of outlier physicians, defined as those whose mean number of stages for MMS was 2 standard deviations greater than the mean number for all physicians billing MMS. Logistic regression was used to study the physician characteristics associated with outlier status. Results: Our analysis included 2305 individual billing physicians performing MMS. The mean number of stages per MMS case for all physicians practicing from January 2012 to December 2014 was 1.74, the median was 1.69, and the range was 1.09 to 4.11. Overall, 137 physicians who perform Mohs surgery were greater than 2 standard deviations above the mean (2 standard deviations above the mean = 2.41 stages per case) in at least 1 of the 3 examined years, and 49 physicians (35.8%) were persistent high outliers in all 3 years. Persistent high outlier status was associated with performing Mohs surgery in a solo practice (odds ratio, 2.35; 95% CI, 1.25-4.35). Volume of cases per year, practice experience, and geographic location were not associated with persistent high outlier status. Conclusions and Relevance: Marked variation exists in the number of stages per case for MMS for head and neck, genitalia, hands, and feet skin cancers, which may represent an additional financial burden and unnecessary surgery on individual patients. Providing feedback to physicians may reduce unwarranted variation on this metric of quality.
Authors: Christopher Metchnikoff; Thaddeus Mully; Jonathan P Singer; Jeffrey A Golden; Sarah T Arron Journal: J Am Acad Dermatol Date: 2012-01-29 Impact factor: 11.527
Authors: Suzanne M Connolly; Diane R Baker; Brett M Coldiron; Michael J Fazio; Paul A Storrs; Allison T Vidimos; Mark J Zalla; Jerry D Brewer; Wendy Smith Begolka; Timothy G Berger; Michael Bigby; Jean L Bolognia; David G Brodland; Scott Collins; Terrence A Cronin; Mark V Dahl; Jane M Grant-Kels; C William Hanke; George J Hruza; William D James; Clifford Warren Lober; Elizabeth I McBurney; Scott A Norton; Randall K Roenigk; Ronald G Wheeland; Oliver J Wisco Journal: J Am Acad Dermatol Date: 2012-09-05 Impact factor: 11.527
Authors: Virginia J Reeder; Cheryl J Gustafson; Kenyatta Mireku; Scott A Davis; Steven R Feldman; Daniel J Pearce Journal: Dermatol Surg Date: 2015-03 Impact factor: 3.398
Authors: Saud Aleissa; Cristian Navarrete-Dechent; Miguel Cordova; Aditi Sahu; Stephen W Dusza; William Phillips; Anthony Rossi; Erica Lee; Kishwer S Nehal Journal: J Am Acad Dermatol Date: 2019-10-18 Impact factor: 11.527